Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

An Open Label, Non-randomized Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain 5-HT1A Receptor Occupancy, Pharmacokinetics and Safety of Single Oral Doses of GSK163090, Using the Ligand [11C]-WAY100635.

The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical imaging technique called Positron Emission Tomography (PET) which uses an imaging agent called [11C]-WAY100635.

Inclusion Criteria:

• Healthy male subjects, aged 18-45 years Body weight > 50 kg
• Non-Smoker
• Normal ECG, heart rate and blood pressure

Exclusion Criteria:

• History of any cardiac disease
• History of regular alcohol consumption averaging >14 drinks/week
• Current or recent gastrointestinal disease; History of psychiatric illness including any history of suicidal attempts
• Positive for Hepatitis B and C, and HIV.
• History of drug abuse.
• Exposure to research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden
• Family history of cancer (one or more first-degree relative diagnosed before the age of 55).
• Suffers from claustrophobia
• History or presence of neurological or psychiatric conditions
• Presence of a cardiac pacemaker or other implanted electronic device or metal implants